Market Overview
Prurigo Nodularis Treatment Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 3.6% during the forecast period (2022-2029).
Prurigo nodularis (PN) is a skin disease that causes hard, itchy lumps to form on the skin. An intense itching causes people to scratch till bleeding or pain. Prurigo nodularis may be a phenotypic presentation of several underlying diseases like atopic dermatitis, chronic kidney-related pruritus, and neurological diseases.

Market Dynamics
The major driving forces are favorable regulations and initiatives for orphan drug development in various regions, increasing healthcare expenditure, the rarity of the disease, and rising demand for prominent orphan drugs used to treat rare diseases.
The ongoing research on treating prurigo nodularis is pushing the market’s growth.
The presence of an increased number of research and development activities is expected to drive the market over the forecast period (2022-2029); for instance, according to the Clinical Trials gov. currently, two studies are ongoing for the intervention of prurigo nodularis such as a phase 2b/3, randomized, double-blind, placebo-controlled, 2-arm, efficacy and safety study in prurigo nodularis (PN) with Nalbuphine ER tablets for pruritus relief through itch-scratch modulation (prism study) sponsored by Trevi Therapeutics and is expected to be completed on February 28, 2023, and a randomized, single-dose, open-label, parallel-group study in healthy volunteers to assess the relative bioavailability of a subcutaneous dose of Nemolizumab when administered with auto-injector compared to dual-chamber syringe sponsored by Galderma R&D, estimated to be completed on January 31, 2023. Furthermore, five different studies are recruiting, propelling the global market growth.
The availability of alternative treatment options slows the Prurigo Nodularis Treatment market growth.
The availability of alternative treatment options is hindering market growth. For instance, Pimecrolimus was as effective as hydrocortisone and offered an alternative topical treatment option that may be implemented in a long-term regimen. Phototherapy can be used to treat several inflammatory skin conditions and is a therapeutic alternative for patients with multiple comorbidities or generalized prurigo nodularis.
Industry analysis.
The prurigo nodularis treatment market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, research and developments, epidemiology, regulatory, pricing, pipeline analysis, Etc.

COVID-19 Impact Analysis
COVID-19 is an atypical health concern that has profoundly impacted the global prurigo nodularis treatment market growth. In the course of the outbreak, restrictions were imposed by different regulatory bodies for controlling the spread of the infection regarding the socializing of people, which made it difficult to get regular healthcare check-ups on time leaving many cases of prurigo nodularis undetected. Moreover, the restrictions on transportation affected the import and export, affecting the supply chain of many market players, overall reducing the availability of prurigo nodularis treatment in the market, reducing sales, and negatively impacting the market growth globally.

Segment Analysis
The corticosteroid creams segment is estimated to oppress the market during the forecast period (2022-2029).
The corticosteroid creams segment is expected to witness substantial growth during the forecast years (2022-2029). Considerable segmental growth can be attributed to the advantages possessed by these creams. These topical corticosteroids control the spread of fungal skin infections and decrease inflammation to a greater extent. Also, when applied externally on the body surface, creams provide faster relief than oral tablets, which require time to show outcomes.

Geographical Analysis
North America is predicted to hold most of the market share.
North America dominated the global prurigo nodularis treatment market in 2021. It is assumed to oppress the global nodularis treatment market over the forecast period (2022-2029) owing to the presence of key market players in this region. For instance, Pfizer, Menlo Therapeutics Inc., Celgene Corporation and Trevi Therapeutics. These key players hold most of the market share and ensure that North America dominates the global prurigo nodularis treatment market. Furthermore, North America has the most advanced and robust infrastructure with good healthcare cost reimbursement policies fueling its command over the global market.

Competitive Landscape
The major players operating in the global prurigo nodularis treatment market are Menlo Therapeutics Inc., Pfizer, Kiniksa Pharmaceuticals, Ltd., GlaxoSmithKline, Galderma, Trevi Therapeutics, and Celgene Corporation. The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the prurigo nodularis treatment market globally. For instance, on June 09, 2022, Pfizer acquired ReViral. Also, on March 11, 2022, Pfizer acquired Arena Pharmaceuticals.
Pfizer Inc.
Overview
Pfizer is an American multinational pharmaceutical and biotechnology corporation founded in 1849 and headquartered in the United States. Pfizer is continuously researching and developing new drug products for various diseases.
Product Portfolio
Pfizer`s prurigo nodularis treatment product portfolio has CIBINQO.
The prurigo nodularis treatment market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.